Phaseline

Targets › MYBPC3

MYBPC3 (Myosin-binding protein C, cardiac-type): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 1 Phase 2, 1 Phase 1; Cardiovascular; next expected readout Aug 2027.

Thick filament-associated protein located in the crossbridge region of vertebrate striated muscle a bands. In vitro it binds MHC, F-actin and native thin filaments, and modifies the activity of actin-activated myosin ATPase. (UniProt, Q14896)

Open in Phaseline: the race on MYBPC3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Edgewise TherapeuticsEDG-7500
Cardiac myosin inhibitor
MYBPC3Phase 2Hypertrophic CardiomyopathyDec 2027
Tenaya TherapeuticsTN-201
Recombinant AAV9 delivering MYBPC3 transgene
MYBPC3Phase 1Hypertrophic CardiomyopathyAug 2027

Conditions

Hypertrophic Cardiomyopathy (2)

Modalities

small molecule (1), other (1)

Companies

Edgewise Therapeutics (1) Tenaya Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.